Smokers who seek lung screening are likely to be receptive to smoking cessation

November 13, 2001

NEW YORK, November 12, 2001 - Smokers who undergo low-dose helical computed tomographic (CT) scanning for lung cancer were motivated to quit smoking, according to a study conducted by researchers at Memorial Sloan-Kettering Cancer Center, and colleagues at Weill Medical College of Cornell University, and the Hospital for Special Surgery. The study, to be published in the December issue of Preventive Medicine, found that 23 percent of smokers reported quitting and another 27 percent reported decreased smoking after undergoing CT lung screening.

"Someone seeking lung cancer screening presumably has at least some concern about their risk of developing lung cancer," said Jamie S. Ostroff, Ph.D., first author of the study and the Director of MSKCC's Smoking Cessation Program. "This study demonstrates that lung cancer screening represents an important opportunity for delivering smoking cessation information."

The retrospective, self-reported study looked at 134 active smokers, all of whom were enrolled in the Early Lung Cancer Action Program (ELCAP). ELCAP screens high-risk active and former smokers with low-dose CT scanning, a procedure which preliminary evidence has shown to have increased sensitivity in the detection of early stage lung tumors-when lung cancer is most treatable. Individuals who enrolled in the study, which did not provide any formal smoking cessation advice or counseling, completed a brief telephone interview following their screening. Eighty-seven percent of enrollees stated that the screening process had been a major influence in increasing their motivation to quit smoking.

Twenty-three percent of the study participants reported that they had quit smoking following screening (markedly higher than the expected annual quit rate of about seven percent estimated for the general population of smokers). Twenty-six percent reported decreased smoking and 48 percent reported no change in smoking status or rate, while just under three percent reported increased smoking after ELCAP enrollment. The median time between screening and quitting was six months. Among those who reported quitting or cutting down after screening, only 10 percent used nicotine replacement therapy or other pharmacological approaches.

Some of the respondents' most frequently endorsed motivating factors for changes in their smoking behavior include heightened awareness of the hazards of smoking, fear of lung cancer detection during follow-up scan, discussion with their physician about the findings, and the desire to have an improved lung CT scan at the follow-up.

"Piggybacking smoking cessation advice with screening may be a promising way to reach smokers," Dr. Ostroff noted. "In our research, we look for 'teachable moments' for enhancing health-promoting behavior change, and lung cancer screening represents one of these moments. Our responsibility as healthcare providers is to seize these opportunities and deliver proven methods to accelerate and sustain health behavior change."

Today, lung cancer is the leading cause of cancer death in the United States, with an estimated 156,000 annual deaths. Lung cancer is also the most preventable form of cancer, with approximately 90 percent of all lung cancer cases attributable to tobacco exposure. As a result, smoking cessation and early detection remain critical goals for lung cancer prevention and control. "Continued smoking greatly increases the risk for lung cancer and other tobacco-related diseases, and there are now several quitting methods proven to be effective," Dr. Ostroff said.
The study was supported in part by the National Institutes of Health and the Division of Health Policy and Technology Assessment, Department of Radiology, Weill Medical College of Cornell University.

Memorial Sloan-Kettering is currently participating in a statewide study of low-dose spiral CT scanning for the early detection of lung cancer in long-term, current, and former smokers. For those interested in the screening, call the MSK Cancer Prevention and Wellness Program at 1-888-MSK-WELL (1-888-675-9355).

Memorial Sloan-Kettering Cancer Center is the world's oldest and largest institution devoted to prevention, patient care, research and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose, and treat cancer. Our specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide.

Memorial Sloan Kettering Cancer Center

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to